Treats inflammatory lesions of rosacea. ANDA 212646, held by Alembic. Metronidazole.
As of Nov 21, 2026, ANDA 212646 (Metronidazole), held by Alembic, was first approved by FDA on Sep 3, 2021, with 2 approved supplements and 0 published complete response letters.
Metronidazole gel, 1% is nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 3, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole1% · gel;topical | Metronidazole | Rx |
| Feb 17, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 17, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 3, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters